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Summary
We describe a family with a novel disorder characterized
by episodic muscle weakness and X-linked inheritance.
Eight males in three generations demonstrate the char-
acteristic features of the disorder. Episodes of severe
muscle weakness are typically precipitated by febrile ill-
ness and affect the facial and extraocular musculature,
as well as the trunk and limbs, and resolve spontaneously
over a period of weeks to months. Younger members of
the family are normal between episodes but during re-
lapses show generalized weakness, ptosis, and fluctua-
tions in strength. In some cases, fatigability can be dem-
onstrated. The proband has late-onset chronic weakness
and fatigability. The clinical phenotype has features sug-
gestive both of the congenital myasthenic syndromes and
of ion-channel disorders such as the periodic paralyses.
We have localized the responsible gene to chromosome
Xp22.3, with a maximum two-point LOD score of 4.52
at a recombination fraction of .0, between OACA2 and
DXS9985.
Introduction
Episodic symptomatology as a clinical phenomenon is
seen in a number of neurogenetic diseases, including the
congenital myasthenic syndromes, periodic paralyses,
myotonias, and episodic ataxias. The congenital myas-
thenic syndromes are a group of genetically determined,
nonautoimmune disorders affecting the neuromuscular
junction (reviewed by Engel [1994] and Middleton
[1998]). The cardinal features of the congenital myas-
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thenic syndromes include fatigue-induced weakness, ab-
sence of acetylcholine-receptor antibodies, and neuro-
physiological evidence of a defect in neuromuscular
transmission. Onset is usually in infancy or early child-
hood, and response to anticholinesterase therapy is var-
iable. The periodic paralyses are skeletal myopathies in
which disordered sarcolemmal ion-channel function
causes periods of temporary muscle weakness. Weakness
occurs in response to environmental stressors, exercise,
and either potassium loading or depletion. There is wide
variation in the frequency of relapses. Patients can be
completely asymptomatic between episodes, or they may
complain of cramping and muscle stiffness (Rudel and
Lehmann-Horn 1998). Within each of these groups of
disorders, there is considerable genetic and clinical het-
erogeneity. However, none of the disorders identified,
to date, are X linked. In most instances, the pathophys-
iology of episodic symptomatology is only poorly
understood.
We report a family with the clinical and pathological
features of a new syndrome of episodic muscle weakness.
Eight males in generations II and IV demonstrate the
typical features of the disorder, consistent with X-linked
inheritance. Muscle biopsy in the index case demon-
strates dilatation and focal proliferation of the sarco-
plasmic reticulum. We have mapped the disease locus to
Xp22.3. The clinical phenotype overlaps both with the
familial myasthenic syndromes and with channelopa-
thies, such as the periodic paralyses. However, other fea-
tures of this disorder, such as the severity of exacerba-
tions, the complete remission of symptoms and signs
between episodes, the X-linked pattern of inheritance,
and the atypical manifestations in some members of the
kindred, suggest that this syndrome represents the first
member of a novel subgroup of the episodic disorders.
Subjects and Methods
This study was approved by the Research Ethics Com-
mittee of the New Children’s Hospital, Sydney (approval
no. 98028), and was conducted in accordance with in-
stitutional guidelines. A multigenerational, nonconsan-
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guineous Australian family of European origin was iden-
tified for this study (fig. 1). Informed consent was
obtained from all adult participants prior to physical
examination and sample collection. In addition to writ-
ten parental consent, a verbal agreement to participate
was obtained from all subjects of age !16 years. Neu-
rological examination of 34 members in generations
II–IV was performed by K.N. and M.R.
Genotyping
DNA samples were collected from 37 individuals, in-
cluding 8 affected and 8 unaffected males in generations
II and IV, obligate carrier females in generation III, and
their partners. Genomic DNA was prepared from pe-
ripheral blood leukocytes in duplicate 9-ml blood sam-
ples by following the procedure of Miller et al. (1988).
DNA was quantitated by UV spectroscopy, diluted to a
standard concentration of 100mg/ml with 1 # Tris-
EDTA, and stored at 20C for analysis.
Eighteen microsatellite markers from the PE Biosys-
tems X-Chromosome Linkage Set were used in an initial
screen for linkage (Australian Genome Research Facil-
ity). The average PIC of the marker set is ∼.78, with an
average map resolution of ∼10.8 cM. For the refinement
of the candidate area on distal Xp, we analyzed nine
other fully or partially informative simple tandem-repeat
polymorphisms (STRPs) between DXS1060 and
DXS1226. The STRPs used in the fine-mapping study
were determined principally from the physical maps of
distal Xp, constructed by the Baylor Genome Sequencing
Center and Telethon Institute of Genetics and Medicine,
Milan (Ferrero et al. 1995; Cox et al. 1998). The order
and genetic distances of markers were determined from
the map of chromosome X, developed by the Marshfield
Center for Medical Genetics and by the Whitehead In-
stitute for Biomedical Research/MIT Center for Genome
Research (fig. 2). Markers without published genetic dis-
tances were assigned approximate genetic distances on
the basis of their physical map position.
Oligonucleotide-primer sequences were determined
from the Integrated X-Chromosome Database and from
the publications of Ferrero et al. (1995) and Cox et al.
(1998). For all STRP loci, the forward primer in each
pair was HEX-labeled to enable fluorescent detection.
Primers were synthesized by Life Technologies.
PCR amplifications were performed in 15-ml vols con-
taining 50 ng genomic DNA, 200 mM dNTPs, 5 pmol
each of forward and reverse primer, 0.5 U AmpliTaq
Gold DNA polymerase (PE Biosystems), and 1# PCR
buffer II (PE Biosystems) with 1.25 mM Mg. PCR
cycle conditions were as follows: initial denaturation for
9 min at 95C, followed by 30 cycles of 95C for 0.5
min, 55C for 0.5 min, and 72C for 1 min, with a final
extension for 5 min at 72C. PCR products were sepa-
rated by gel electrophoresis in 6% Gene-Page Plus (Am-
resco) denaturing acrylamide-matrix gels. STRP alleles
were resolved on a Corbett Research GS.2000 Fluores-
cent DNA Fragment Analyzer. Alleles were indepen-
dently scored by two individuals.
Linkage Analysis
Two-point and multipoint linkage analyses were per-
formed with the LINKAGE computer packages (Lathrop
et al. 1984). Linkage analyses assumed X-linked reces-
sive inheritance and a fully penetrant disorder without
phenocopies. Equal allele frequencies were assigned to
STRP loci, since all transmitting individuals were fully
typed.
Results
Clinical Findings
Eight males in three generations demonstrated the typ-
ical features of this disorder, with episodes of muscle
weakness precipitated by viral illness. There is no male-
to-male transmission, and obligate female carriers have
no episodes of weakness, consistent with X-linked re-
cessive inheritance (fig. 1).
Characteristics of episodic weakness.—A typical
member of this family is patient IV-27. He was unaf-
fected until age 25 mo, at which time he developed ptosis
and weakness after an episode of gastroenteritis. Within
48 h, he was unable to walk. Clinical improvement oc-
curred over a period of 3 wk, with occasional fluctua-
tions in strength. There was no response to a neostigmine
test. Nerve conduction studies and electromyography
(EMG) were normal. No medications were given, and
he has demonstrated slight weakness over a subsequent
period of 12 mo.
The clinical history is similar in five other members
of generation IV. The first episode of weakness occurred
at age 6 mo–8 years. Three of the eight patients expe-
rienced a single episode of weakness, whereas one had
110 discrete episodes. In each of the eight affected family
members, viral illness (seven patients) or halothane an-
aesthesia (one patient) precipitated the initial presenta-
tion and subsequent relapses. Weakness has persisted for
variable periods, with the initial episode lasting for as
long as 8 mo; subsequent relapses tend to be shorter.
The clinical features are summarized in table 1.
Symptom severity varied widely between episodes and
among patients. The initial episode tended to be more
severe in those with a younger age at onset. When weak-
ness was relatively mild, it was localized to the proximal
musculature. In three patients, episodes of weakness
were so severe that loss of head control was associated
with inability to walk or to raise the arms against grav-
ity. During such episodes, the reflexes were depressed
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Figure 1 Pedigree structure and partial X-chromosome haplotypes in the region Xp22.3 for the family with X-linked episodic muscle
weakness. The haplotype shared by affected family members is denoted by a blackened box. The grandmaternal haplotypes are denoted by
white and gray-shaded boxes. The order of STRP is from telomere (top) to centromere (bottom). Individuals IV-18 and IV-26 show maternally
derived recombinations.
or absent, although they usually returned between
exacerbations.
All patients had ptosis during at least one episode,
and two of eight patients had intermittent strabismus
during exacerbations. Three had bulbar weakness, al-
though none required gavage feeds or parenteral nutri-
tion. No patient required mechanical ventilation or
showed any evidence of significant respiratory compro-
mise, even with the most severe exacerbations. Fatiga-
bility was evident in three patients. Clearly distinguish-
able from fatigability were momentary fluctuations in
muscle strength and ptosis, unrelated to effort or exer-
cise, which were seen in five of eight patients.
Additional phenotypic features.—Both patient IV-2
and patient IV-24 reported myalgia and cramps precip-
itated by minimal exercise. At age 4 years patient IV-24
developed episodic dystonia, which frequently was as-
sociated with exercise although not with cold. Basal-
ganglia calcification was seen on neuroimaging, al-
though cerebrospinal fluid (CSF) protein and lactate and
mitochondrial enzyme analysis on muscle biopsy were
normal. The patient continues to have episodic dystonia,
sometimes associated with tremor, which has proved re-
fractory to therapy with levodopa and benzhexol. Two
patients also experienced transient episodes of dystonic
posturing, either precipitated by exercise (patient IV-2)
or during the initial episode of weakness (patient IV-8).
These episodes resolved spontaneously. No patient had
myotonia at any time. Patient IV-5 also has an inter-
mittent tremor that is increased by anxiety. Interestingly,
three of the obligate female carriers in this family have
a history of essential tremor, increased by stress and not
relieved by alcohol.
Clinical course.—Seven of the eight affected males are
age !18 years. At last review, five of the seven affected
males in generation IV were in periods of remission (18
mo–9 years). Patient IV-27 is in a phase of continuing
recovery from his initial episode, whereas patient IV-24
has had normal strength for 5 years but has intermittent
dystonia.
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Figure 2 Ideogram of the short arm of the X chromosome, with
STRP genetic distances. Intermarker distances were obtained from
public databases or, when unknown, have been assigned on the basis
of physical-mapping data and known genetic distances for flanking
markers.
The index case, patient II-3, is now 69 years old. At
age 7 years he developed severe flaccid paralysis after a
febrile illness, which was diagnosed as poliomyelitis. He
recovered fully over a period of 6–12 mo. After this, he
experienced 110 episodes of lower-limb weakness at age
!25 years. At age 25–53 years, he was relatively asymp-
tomatic, apart from intermittent ptosis and mild dys-
phagia. Since that time, he has experienced continuing
clinical deterioration, with progressive weakness and fat-
igability. He also has a late-onset axonal neuropathy and
episodes of agitated depression.
Clinical Investigations
Muscle histology and ultrastructure.—The index pa-
tient underwent muscle biopsy at age 69 years, at a time
when the patient demonstrated chronic weakness. Light
microscopy revealed nonspecific changes with widened
interfibrillary spaces. On electron microscopy, there was
dilatation of the sarcoplasmic reticulum (fig. 3), with
focal areas of proliferation. There were large spaces be-
tween the myofibers and within the subsarcolemmal
regions, which likely represent increased glycogen de-
posits. The mitochondrial appearance was normal. A
muscle biopsy in patient IV-24 (performed during an
episode of weakness) revealed type 2B fiber atrophy with
occasional lymphocytic infiltrates. The significance of
these changes is not known. Muscle biochemistry and
respiratory-chain–enzyme analysis were normal. Muscle
was not available for electron microscopy.
Neurophysiology.—Neurophysiological studies (nerve
conduction studies and EMG) in affected members of
this family have not demonstrated a diagnostic pattern
of abnormal findings. The proband developed symptoms
associated with an axonal neuropathy, in his 6th decade.
Conduction studies at age 69 years revealed mild slowing
of nerve conduction and significantly decreased CMAP
(compound muscle action potential) and SNAP (sensory
nerve action potential) amplitudes. Results of repetitive
nerve stimulation were normal. Standard EMG showed
some loss of motor-unit density but no myotonia or ac-
tive denervation, whereas single-fiber electromyography,
with increased jitter and some blocking, was suggestive
of chronic denervation/reinnervation. The changes seen
were not typical either of the channelopathies or of the
congenital myasthenic syndromes, although the single-
fiber EMG was potentially consistent with myasthenia.
In affected members of generation IV, nerve conduction
studies were normal in one patient, nonspecific abnor-
malities on EMG were seen in one of two patients, and
repetitive nerve stimulation of limb muscles was normal
in three of three patients. EMG of the facial musculature
was not performed.
Assays for antibodies to the acetylcholine receptor
were negative in three of three patients. Neostigmine
tests were performed in five of eight patients. These were
unequivocally positive in two, equivocal in two, and
negative in one patient. Three patients received anticho-
linesterase therapy during episodes of weakness with
sustained response; however, the weakness resolved
spontaneously in patients not receiving therapy. The pro-
band was given regular pyridostigmine (500 mg/d) from
age 60 years and reported subjective improvement in his
chronic weakness. However, pyridostigmine was re-
cently withdrawn without adverse effect or change in
his level of function.
Additional investigations.—Neuroimaging was per-
formed in two patients and was normal in one. Patient
IV-24 had basal-ganglia calcification on brain computed
tomography (CT) scan. This finding was confirmed on
magnetic resonance imaging, which showed hyperin-
tensity of the putamina and caudate nuclei bilaterally
on T2-weighted images. CSF and serum studies for mi-
tochondrial and inherited metabolic disorders were nor-
mal in this patient and in one other. Investigations per-
formed in a minority of patients, which were normal in
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Table 1
Summary of Clinical Data
Patient
Age at
Onset
(Years)
Current
Age
(Years)
Episodes of
Weakness
Precipitant for
Episode(s) Duration of Episode(s) Course
II-3 7 69 110 Viral illness; subsequent
precipitants less clear
Initial episode 16 mo Fatigability worsening with increased
age; increasing weakness
IV-2 8 11 1 Tonsillectomy Initial episode 11 mo Asymptomatic for 2 years
IV-5 2.2 18 5 Viral illnesses and
gastroenteritis
Initial episode 18 mo;
subsequent episodes shorter
Asymptomatic for 9 years
IV-8 1.5 12 3 Viral illnesses on each
occasion
Initial episode 4 mo;
subsequent episodes shorter
Asymptomatic for 6 years
IV-10 1.1 9 4 Viral illness on one
occasion
Initial episode 3 wk; other
episodes !24 h
Asymptomatic for 7 years
IV-24 .5 9 1 Viral illness Episodic ptosis; fatigable;
spontaneously resolving af-
ter 3–4 d
Development of dystonia
IV-26 .9 5 15 Viral illnesses Initially 2 wk; subsequent
episodes shorter
Asymptomatic for 18 mo
IV-27 2.1 3 1 Gastroenteritis 3 wk Remains slightly weak 12 mo
after initial episode
each instance, included measurement of serum creatine
kinase and electrolytes during episodes of weakness (in
three patients), CT scan of the mediastinum (in two pa-
tients), and CSF protein and biochemical analysis (in two
patients). In the index case, a screen for causes of late-
onset axonal neuropathies (including serum and urine
protein electrophoresis, immunoglobulin levels, urine
heavy metal, and porphyrin screening) was negative.
Linkage Analysis
The mode of inheritance of the disorder in this family
is most consistent with a single, fully penetrant X-linked
recessive gene. As an initial step toward identifying the
molecular basis of this disorder, we undertook linkage
analysis of the X chromosome. The initial linkage studies
were conducted at a map resolution of ∼10 cM and
demonstrated linkage to distal Xp. We therefore tested
nine other STRPs between DXS1060 and DXS1226,
narrowing the genetic interval containing the putative
locus to a region within chromosome band Xp22.3 (fig.
2). The maximum two-point LOD score of 4.52 was
obtained between OACA2 and DXS9985, at a recom-
bination fraction (v) of .0, consistent with significant
linkage (table 2). The LOD score is reduced at
DXS7108, DXS85, and DXS7104, because of the re-
duced informativeness of these markers. The Human
Gene Nomenclature Committee has approved the use of
the gene symbol EMWX (episodic muscle weakness, X-
linked) for the gene encoding this disorder.
A centromeric crossover event was identified in the
∼1-Mb region between the markers DXS1224 and
DXS9985 in individual IV-18 (fig. 1). A telomeric cross-
over was identified in the ∼200-kb region between the
markers DXS7103 and OACA2 in individual IV-26. The
position of these recombination events allows us to as-
sign the interval for the EMWX locus to the ∼2.8-Mb
region between DXS1224 and DXS7103 (on the basis
of the physical map of the region produced by Cox et
al. [1998] and the current release of the distal Xp map
produced by the Baylor Human Genome Center). Ad-
ditional informative STRPs are currently being sought
in the interval between DXS9985 and DXS1224, to fur-
ther reduce the size of the critical region.
Discussion
We have reported a novel syndrome of episodic weak-
ness linked to Xp22.3. Although this disorder overlaps
clinically with both the channelopathies and the con-
genital myasthenic syndromes, the temporal pattern of
the disorder, the severity of exacerbations, and the X-
linked mode of inheritance distinguish it from other
known episodic syndromes.
The episodic nature of the weakness in this family is
similar to that seen in disorders of ion-channel function,
such as the periodic paralyses, nondystrophic myotonias,
and episodic dyskinesias (table 3). These disorders have
a similar pathophysiological basis, with dysfunction of
ion-permeable transmembrane channels, resulting in ab-
normalities of sodium-, potassium-, or chloride-ion
transport and altered neuromuscular transmission (Ru-
del and Lehmann-Horn 1998). Common clinical fea-
tures include onset in the 1st decade of life, relatively
rapid fluctuations in clinical status, and precipitation of
episodes by environmental or other stimuli. Patients may
be symptomatic only on exertion, when cold, or after
ingestion of potassium, coffee, or alcohol. Diagnosis
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Table 2
Two-Point LOD Scores for Polymorphic Markers on the X
Chromosome
MARKER
LOCUS (cM)
LOD SCORE AT v =
.0 .001 .01 .05 .1 .2 .3 .4
DXS7103 (12.03)  .29 .67 1.23 1.34 1.23 .95 0.54
OACA2 (13) 4.52 4.51 4.45 4.18 3.83 3.06 2.19 1.19
DXS10005 (13) 4.52 4.51 4.45 4.18 3.83 3.06 2.19 1.19
DXS7108 (14.20) 2.71 2.71 2.67 2.51 2.30 1.84 1.32 .71
DXS85 (14.2) 2.71 2.71 2.67 2.51 2.30 1.84 1.32 .71
DXS10006 (16) 4.52 4.51 4.45 4.18 3.83 3.06 2.19 1.19
DXS9985 (16) 4.52 4.51 4.45 4.18 3.83 3.06 2.19 1.19
DXS7104 (18.12) 2.71 2.71 2.67 2.51 2.30 1.84 1.32 .71
DXS1224 (20.1)  1.51 2.45 2.90 2.87 2.46 1.82 1.01
is given on the basis of the clinical phenotype and
characteristic neurophysiological findings of myotonia
or electrical inexcitability. A variable response to
membrane-stabilizing agents is seen (Hudson et al. 1995;
Bulmand 1997). There is considerable genetic and clin-
ical heterogeneity within this group of disorders. The
mode of inheritance is either autosomal dominant or
autosomal recessive; X-linked inheritance has not been
identified in any channelopathy, to date.
Fluctuations in muscle strength, fatigability, ptosis,
and response to anticholinesterases in some members of
the family raise the diagnostic possibility of a congenital
myasthenic syndrome (table 4). These syndromes are due
to altered neuromuscular transmission secondary to ab-
normalities of acetylcholine-receptor subunits, or to syn-
thesis, transport, or metabolism of acetylcholine. Inher-
itance is usually autosomal recessive, apart from the
slow-channel syndromes, which are inherited in an
autosomal dominant fashion (Engel 1994; Middleton
1998). Patients with congenital myasthenic syndromes
usually have both an abnormal decremental response to
repetitive nerve stimulation of affected muscles and in-
creased jitter on single-fiber EMG. However, these stud-
ies may be normal in interictal periods in patients with
a defect in acetylcholine resynthesis or packaging (see
below). Fatigue-induced muscle weakness usually re-
sponds to anticholinesterase therapy, with the exception
of patients with the slow-channel syndrome or endplate-
cholinesterase deficiency (Engel 1994).
The temporal pattern of weakness seen in this family
is unique. The severity and speed of onset of weakness
are similar to those of the channelopathies, suggesting
that the underlying pathophysiology may be dysfunction
of ion-permeable transmembrane channels (table 4). In
the periodic paralyses, weakness may develop over
minutes to hours but does not usually persist for more
than a few days, as opposed to the weeks-to-months–
long period of weakness seen in several of the patients
described above. The proband developed progressive
chronic weakness and fatigability in his 5th decade, after
25 years of being relatively symptom free. A similar dis-
ease course has been described in the subset of patients
with periodic paralysis in whom a progressive myopathy
develops in middle age (Bradley et al. 1990; Links et al.
1990).
Episodic symptomatology is unusual in the congenital
myasthenic syndromes, apart from the rare autosomal
recessive disorder known as “familial infantile myasthe-
nia,” which is the result of a presynaptic defect in ace-
tylcholine resynthesis or packaging (Mora et al. 1987;
Matthes et al. 1991; Engel 1994). Onset is usually at
birth or in infancy, with fluctuating ptosis and feeding
difficulties. Exacerbations of severe weakness and res-
piratory insufficiency occur during infancy and child-
hood and are precipitated by fever, excitement, or vom-
iting. The exacerbations become less frequent with
increased age, and patients may experience only fati-
gability on exertion. Other patients develop mild-to-
moderate weakness of cranial, limb, and respiratory
muscles at rest (Mora et al. 1987; Engel 1994).
The muscle biopsy of the index case demonstrated
dilatation and focal proliferation of the sarcoplasmic
reticulum on electron microscopy, although frank vac-
uolation was not evident on light microscopy. The ul-
trastructural morphology has features in common with
the vacuolar myopathy associated with the periodic pa-
ralyses (Rudel and Lehmann-Horn 1998) and with sar-
cotubular myopathy. The latter disorder was described
in a single case report of two brothers from a Hutterite
family with a nonprogressive congenital myopathy and
myopathic changes on EMG (Jerusalem et al. 1973).
Their subsequent clinical course has not been reported,
but the muscular weakness was not thought to be
episodic.
The linkage results obtained in this family have nar-
rowed the critical interval to that betweenDXS7103 and
DXS1224, a genomic region of ∼2.8 Mb. The LOD
score of 4.52, obtained for the fully informative STRPs
between OACA2 and DXS9985, significantly exceeds
the threshold for linkage on the X chromosome, which
is conventionally cited as a LOD score of 2.
Within the critical interval, as currently defined, are
several positional candidate genes. The chloride-channel
IV gene (CLCN4) and Apical protein, Xenopus lae-
vis–like gene (APXL) were identified as part of the Bay-
lor Human Genome Center’s genome-sequencing project
(Ferrero et al. 1995). No genetic diseases have been as-
sociated with mutations in CLCN4 or APXL, to date.
CLCN4 is a voltage-gated chloride channel that has been
shown to be particularly abundant in skeletal and car-
diac muscle and is also expressed in the brain, an ex-
pression pattern that is consistent with the symptoma-
tology of this family (Van Slegtenhorst et al. 1994). No
mutation has been identified in CLCN4 in this family
by DNA sequencing of all coding exons (Genbank);
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Figure 3 Electron microscopy of a quadriceps-muscle biopsy from individual II-3. The ultrastructural appearance shows dilation of the
sarcoplasmic reticulum, with widened intermyofibrillar spaces.
however, the investigation of large-scale genomic rear-
rangements is still in progress. The APXL gene encodes
a protein with a PDZ domain homologous to those of
sodium-channel–binding proteins. (The name PDZ de-
rives from the names of the three proteins that contain
these motifs: the mammalian postsynaptic density pro-
tein, PSD95; the Drosophila disc large tumor suppressor,
DlgA; and the mammalian tight junction protein, Z01.)
APXL also has a domain with significant identity to the
amiloride-sensitive sodium-channel–interacting protein
APX of Xenopus laevis (Schiaffino et al. 1995). Al-
though there is no evidence that APXL is expressed at
significant levels in skeletal muscle, mutations in sodium-
ion channels are well-described causes of muscle weak-
Table 3
Genetic Episodic Disorders
Disorder Locus Gene Protein Product
Periodic paralyses/myotonias:
Sodium-channel disorders:a
Hyperkalaemic periodic paralysis, paramyotonia congenita, myotonia fluctuans, permanent myotonia,
atypical (acetazolamide-responsive) myotoniab
17q23-q25 SCN4A Skeletal-muscle sodium-channel a subunit
Calcium-channel disorders:c
Hypokalaemic periodic paralysis 1q31-q32 CACNL1A3 a1S Subunit of dihydropyridine receptor
Familial hemiplegic migraine, spinocerebellar ataxia type 6 (EA2) 19p13 CACNL1A4 a1A Subunit of P/Q-type calcium channel
Malignant hyperthermia 19q13.1 RYR1 Skeletal-muscle–ryanodine receptor
7q21-q22 CACNL2A a2d subunit of voltage-gated calcium channel
Chloride-channel disorders:d
Thomsen’s myotonia congenita, Becker’s myotonia congenita 7q35 CLC1 Skeletal-muscle chloride channel
Startle disease (hyperekplexia) 5q32 Glya1 Glycine receptor a1 subunit (chloride channel)
Potassium-channel disorders:
Episodic ataxia/myokymia (EA1)d 12p13 KCNA1 Voltage-gated potassium channel
Paroxysmal choreoathetosis/spasticitye 1p
Familial paroxysmal dyskinesias:f
Paroxysmal nonkinesigenic dyskinesia 2q33-q35 SLC2C ? Ion-channel gene
Familial kinesigenic dyskinesia, paroxysmal exertional dyskinesia, paroxysmal hypnogenic dyskinesia,
nocturnal paroxysmal dystonia
Episodic ataxias:
Periodic vestibulocerebellar ataxiag 19p
Acetazolamide-responsive hereditary paroxysmal cerebellar ataxiah 19p
Long QT syndrome:i
Long QT syndrome 1 11p15.5 KVLQT1 Cardiac-potassium channel
Long QT syndrome 2 7q35-q36 HERG Cardiac-potassium channel
Long QT syndrome 3 3p21-p24 SCN5A Cardiac-sodium channel
Long QT syndrome 4 4q25-q27
Long QT syndrome 5 21q22 MinK
Miscellaneous:
Hereditary thermosensitive neuropathyj(autosomal dominant)
a From Ptacek et al. 1993.
b From Rudel et al. 1993.
c From Greenberg 1997.
d From Rudel and Lehmann-Horn 1998.
e From Auburger et al. 1996.
f From Fink et al. 1996 and Fouad et al. 1996.
g From Damji et al. 1996.
h From Vahedi et al. 1995 and Von Brederlow 1995.
i From Wang 1996.
j From Magy et al. 1997.
1112 Am. J. Hum. Genet. 65:1104–1113, 1999
Table 4
Comparison of Clinical Characteristics of the Myasthenic Syndromes,
Channelopathies, and X-Linked Episodic Weakness
Clinical Feature(s)
Congenital
Myasthenic
Syndromes
Periodic
Paralyses
X-Linked
Episodic
Weakness
Ophthalmoplegia and ptosis   
Complete recovery between episodes   
Exacerbations with illness   
Environmental precipitants   
Fatigability   
Bulbar involvement   
Respiratory muscle involvement   
Myalgia, cramps   
Dystonia   
Tremor   
Neuropathy   
Response to anticholinesterases   
Decrement on repetitive nerve stimulation   
NOTE.— “” indicates presence; “” indicates absence; and “” indicates
variability.
ness (table 3). Other genes within the region include
those responsible for oculo-cutaneous albinism type 1
(MIM 300500); the WD-40 repeat–containing gene
TBL1, associated with late-onset sensorineural deafness
(Bassi et al. 1999); microphthalmia with linear skin-de-
fects syndrome (MIM 309801); Opitz G/BBB syndrome,
associated with midline abnormalities, such as cleft lip,
laryngeal cleft, heart defects, hypospadias, and agenesis
of the corpus callosum (MIM 300000); amelogenesis
imperfecta (MIM 301200); and phosphoribosylpyro-
phosphate synthetase II, which causes a Lesch-Ny-
han–like syndrome (MIM 311860).
The identification of additional families with X-linked
episodic weakness will permit the further assessment of
candidate EMWX genes. Further characterization of
the underlying genetic defect will clarify questions of
nosology and, it is hoped, give insights into the etiol-
ogy and pathogenesis of inherited episodic muscle
syndromes.
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